Trial Profile
A Phase 2b Randomised, Double Blind, Placebo-Controlled, Parallel Arm, Multi-Centre Study to Assess Efficacy and Safety of Multiple Dose Levels of AZD7594 DPI Given Once Daily for Twelve Weeks, Compared to Placebo, in Asthmatics Symptomatic on Low Dose ICS
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2021
Price :
$35
*
At a glance
- Drugs Velsecorat (Primary) ; Budesonide; Fluticasone furoate; Salbutamol
- Indications Asthma
- Focus Therapeutic Use
- Acronyms GRANIT
- Sponsors AstraZeneca
- 19 May 2021 Results presented at the 117th International Conference of the American Thoracic Society
- 18 Nov 2019 Status changed from active, no longer recruiting to completed.
- 17 Nov 2019 This trial is completed in Germany (Global End Date: 2019-09-30), according to European Clinical Trials Database record.